CASI Pharmaceuticals, Inc. (NASDAQ:CASI - Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $5.04 and traded as high as $6.20. CASI Pharmaceuticals shares last traded at $5.99, with a volume of 26,014 shares trading hands.
Analyst Upgrades and Downgrades
Separately, StockNews.com began coverage on CASI Pharmaceuticals in a research report on Saturday, August 3rd. They issued a "hold" rating for the company.
Check Out Our Latest Research Report on CASI Pharmaceuticals
CASI Pharmaceuticals Stock Performance
The company has a 50-day moving average of $6.14 and a 200 day moving average of $5.07. The company has a quick ratio of 2.36, a current ratio of 3.88 and a debt-to-equity ratio of 2.05. The firm has a market capitalization of $89.98 million, a PE ratio of -2.87 and a beta of 0.69.
CASI Pharmaceuticals (NASDAQ:CASI - Get Free Report) last posted its earnings results on Friday, August 16th. The biotechnology company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.11. CASI Pharmaceuticals had a negative return on equity of 126.20% and a negative net margin of 118.81%. The business had revenue of $3.98 million during the quarter, compared to analysts' expectations of $4.43 million.
Hedge Funds Weigh In On CASI Pharmaceuticals
An institutional investor recently raised its position in CASI Pharmaceuticals stock. Renaissance Technologies LLC lifted its position in CASI Pharmaceuticals, Inc. (NASDAQ:CASI - Free Report) by 10.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 40,800 shares of the biotechnology company's stock after purchasing an additional 4,000 shares during the quarter. Renaissance Technologies LLC owned 0.30% of CASI Pharmaceuticals worth $224,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 22.23% of the company's stock.
CASI Pharmaceuticals Company Profile
(
Get Free Report)
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
See Also
Before you consider CASI Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CASI Pharmaceuticals wasn't on the list.
While CASI Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
